TITLE

Lung function decline in asthma: association with inhaled corticosteroids, smoking and sex

AUTHOR(S)
Dijkstra, A.; Vonk, J. M.; Jongepier, H.; Koppelman, G. H.; Schouten, J. P.; Ten Hacken, N. H. T.; Timens, W.; Postma, D. S.
PUB. DATE
February 2006
SOURCE
Thorax;Feb2006, Vol. 61 Issue 2, p105
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Inhaled corticosteroids (ICS) provide short term benefits in asthma but the long term effects are still unknown. Methods: 281 patients diagnosed with moderate to severe asthma in 1963-75 were re-examined in 1991-9. Information was collected on forced expiratory volume in 1 second (FEV1), bronchial hyperresponsiveness, atopy, smoking, use and dosage of oral and ICS. Patients were included in the analyses if they had at least three FEV1 measurements during two consecutive years after the age of 30 and used ICS during follow up. Results: Analyses were performed on 122 patients. During a median follow up period of 23 years, 71 men and 51 women had on average 37 and 40 individual FEV1 measurements, respectively. Linear mixed effect models showed that men had a mean annual decline in FEV1 of 20.6 mI/year less after ICS initiation than before (p=0.011), and in women the decline in FEV1 was 3.2 mI/year less (p=0.73). In individuals with <5 pack years of smoking the decline in FEV1 was 36.8 mI/year less after ICS institution in men (p=0.0097) and 0.8 mI/year less in women (p=0.94), the difference between the sexes being significant (p=O.O45). These effects were not observed in those with ⩾5 pack years smoking. A higher daily dose of ICS was associated with a smaller decline in FEV1 in men (p=0.006), an effect not observed in women. Conclusion: Treatment with ICS in adult patients with moderate to severe asthma was associated with a reduction in the decline in FEV1 over a 23 year follow up period in men who had smoked <5 pack years. This effect was dose dependent and was not present in women or in men with ⩾5 pack years of smoking at follow up. The lack of effect of ICS on the decline in FEV1 in women needs further study.
ACCESSION #
19787742

 

Related Articles

  • Inhaled corticosteroids and decline of lung function in community residents with asthma. Lange, P.; Scharling, H.; Ulrik, C. S.; Vestbo, J. // Thorax;Feb2006, Vol. 61 Issue 2, p100 

    Background: Inhaled corticosteroids (ICS) constitute the cornerstone of treatment for asthma. Many studies have reported beneficial short term effects of these drugs, but there are few data on the long term effects of ICS on the decline in forced expiratory volume in 1 second (FEV1). This study...

  • Treatment Comparison of Budesonide/ Formoterol with Salmeterol/Fluticasone Propionate in Adults Aged ≥16 Years with Asthma: Post Hoc Analysis of a Randomized, Double-Blind Study. Kuna, Piotr // Clinical Drug Investigation;2010, Vol. 30 Issue 9, p565 

    Background: Three fixed maintenance-dose inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) combinations for the treatment of asthma are currently available: salmeterol/fluticasone propionate (Seretide™/Advair™/ Adoair™) budesonide/formoterol (Symbicort®) and...

  • LUNG CLEARANCE INDEX IN CHILDREN WITH ACUTE EXACERBATION OF ASTHMA. Sheridan, H. S.; Cunningham, S. // Thorax;Dec2011 Supplement, pA99 

    Introduction Lung clearance index (LCI) can detect small airways disease in asthma; however there is no published LCI data collected during acute exacerbation. We aimed to investigate LCI in asthmatic children requiring oral corticosteroids and admission to hospital. Methods Children were...

  • Are asthma-like symptoms in elite athletes associated with classical features of asthma? T K Lund // British Journal of Sports Medicine;Dec2009, Vol. 43 Issue 14, p1131 

    BACKGROUND: Asthma is frequent in elite athletes and clinical studies in athletes have found increased airway inflammation. OBJECTIVE: To investigate asthma-like symptoms, airway inflammation, airway reactivity (AR) to mannitol and use of asthma medication in Danish elite athletes. METHODS: The...

  • Functional significance of air trapping detected in moderate asthma. Laurent, F.; Latrabe, V.; Raherison, C.; Marthan, R.; Tunon-de-Lara, J. M. // European Radiology;Sep2000, Vol. 10 Issue 9, p1404 

    The aim of this study was to evaluate bronchial and lung abnormalities in patients suffering from moderate asthma as defined by international guidelines, with special attention to air trapping on CT in comparison with that detected in smoking and non-smoking normal subjects. Twenty-two patients...

  • Inhaled corticosteroids moderate lung function decline in adults with asthma. Ernst, P. // Thorax;Feb2006, Vol. 61 Issue 2, p93 

    The paper describes a reduction in the decline in forced expiratory volume in 1 second (FEV1) over 10 years in patients with asthma aged over 30 years who were using inhaled corticosteroids throughout the observation period. Lange and colleagues conducted the study using information from the...

  • Editorial [Guest Editor: Strategies for the Improvement of Asthma Therapy (Executive Editor: Andreas Pahl)]. Pahl, Andreas // Current Pharmaceutical Design;Sep2006, Vol. 12 Issue 25, p3173 

    Asthma bronchiale, affecting 155 millions people worldwide, has emerged as a major public health problem worldwide over the past 20 years. Although data indicate that current asthma therapies led to limited decreases in death rates, it continues to be a significant health care problem. As we...

  • Asthma: Principles of Treatment. Story, Rachel E.; Tripathi, Anju // Allergy & Asthma Proceedings;Jul/Aug2004, Vol. 25, pS26 

    The article presents information on the principles of treatment of Asthma. Proper treatment of asthma requires an accurate diagnosis of the type of asthma (allergic versus non allergic) as well as its severity. Once a diagnosis is established, coexisting conditions that affect asthma severity...

  • Omalizumab for Asthma: Indications, Off-Label Uses and Future Directions. Ben-Shoshan, Moshe // Recent Patents on Inflammation & Allergy Drug Discovery;Nov2010, Vol. 4 Issue 3, p183 

    Omalizumab is a recombinant humanized monoclonal antibody. Use of omalizumab is reported to benefit significantly a subset of asthmatics patients with inadequately controlled moderate-to-severe persistent allergic asthma that is not controlled with high-dose inhaled corticosteroids. However,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics